Cargando…

Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody

BACKGROUND: In this study, we describe the generation of a fully human monoclonal antibody (named ‘7NP2’) targeting human fibroblast activation protein (FAP), an antigen expressed in the microenvironment of different types of solid neoplasms. METHODS: 7NP2 was isolated from a synthetic antibody phag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nadal, Lisa, Peissert, Frederik, Elsayed, Abdullah, Weiss, Tobias, Look, Thomas, Weller, Michael, Piro, Geny, Carbone, Carmine, Tortora, Giampaolo, Matasci, Mattia, Favalli, Nicholas, Corbellari, Riccardo, Di Nitto, Cesare, Prodi, Eleonora, Libbra, Chiara, Galeazzi, Simone, Carotenuto, Claudiopietro, Halin, Cornelia, Puca, Emanuele, Neri, Dario, De Luca, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476130/ https://www.ncbi.nlm.nih.gov/pubmed/36104101 http://dx.doi.org/10.1136/jitc-2022-005282

Ejemplares similares

An Engineered IFNγ-Antibody Fusion Protein with Improved Tumor-Homing Properties
por: Di Nitto, Cesare, et al.
Publicado: (2023)

Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
por: Carbone, Carmine, et al.
Publicado: (2021)

Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy
por: Tamburrino, Anna, et al.
Publicado: (2013)

Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers
por: Chiaravalli, Marta, et al.
Publicado: (2022)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches
por: Cencioni, Chiara, et al.
Publicado: (2022)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study
por: Rossi, Ernesto, et al.
Publicado: (2023)

Adapting Neutralizing Antibodies to Viral Variants by Structure‐Guided Affinity Maturation Using Phage Display Technology
por: Peissert, Frederik, et al.
Publicado: (2023)

Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer
por: Carbone, Carmine, et al.
Publicado: (2018)

Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance
por: Cascetta, Priscilla, et al.
Publicado: (2018)

Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification
por: Nasca, Vincenzo, et al.
Publicado: (2020)

An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions
por: Prodi, Eleonora, et al.
Publicado: (2023)

Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story
por: Piro, Geny, et al.
Publicado: (2019)

Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo
por: Nadal, Lisa, et al.
Publicado: (2020)

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
por: Berdel, Andrew F., et al.
Publicado: (2022)

Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties
por: Elsayed, Abdullah, et al.
Publicado: (2023)

Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response
por: Piro, Geny, et al.
Publicado: (2021)

An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis
por: Carbone, Carmine, et al.
Publicado: (2014)

Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen
por: Plüss, Louis, et al.
Publicado: (2023)

PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around
por: Gkountakos, Anastasios, et al.
Publicado: (2019)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

IMMU-03. UPDATES ON BRAINCHILD-01, -02, AND -03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
por: Vitanza, Nicholas, et al.
Publicado: (2020)

IMMU-10. INTERIM ANALYSIS OF THE HIT-HGG REZ IMMUNVAC STUDY - DENDRITIC CELL VACCINATION WITH PARTIAL TREG DEPLETION IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RELAPSED HIGH-GRADE GLIOMAS
por: Eyrich, Matthias, et al.
Publicado: (2020)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

IMMU-23. A NOVEL MASS CYTOMETRY-BASED MULTI-PARAMETER CHARACTERIZATION OF NEOANTIGEN-REACTIVE CD8+ T-CELLS IN PATIENTS PARTICIPATING IN PNOC007 H3.3K27M PEPTIDE VACCINE CLINICAL TRIAL
por: Taitt, Jared, et al.
Publicado: (2020)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

IMMU-21. INVESTIGATION OF WHITE BLOOD CELL CHARACTERISTICS IN CSF SAMPLES AT PEDIATRIC BRAIN TUMOR DIAGNOSIS
por: Greer, Hunter, et al.
Publicado: (2020)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS
por: de Billy, Emmanuel, et al.
Publicado: (2020)

IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
por: Mueller, Sabine, et al.
Publicado: (2020)

IMMU-22. PHASE IB IMMUNOTHERAPY CLINICAL TRIAL WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Madrid, Andres Morales La, et al.
Publicado: (2020)

IMMU-16. INTRA-TUMOURAL IL-12 DELIVERY ENABLES CAR T-CELL IMMUNOTHERAPY FOR HIGH-GRADE GLIOMA
por: Agliardi, Giulia, et al.
Publicado: (2020)

IMMU-09. NIVOLUMAB THERAPY FOR A PEDIATRIC-ONSET PRIMARY INTRACRANIAL MELANOMA
por: Oba, Utako, et al.
Publicado: (2020)

IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY
por: Bouffet, Eric, et al.
Publicado: (2020)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_epfdbuse961khjnq318n8ulene